From FDA approvals to business expansion plans, here are medtech stories we missed this week but thought were still worth mentioning. 1. BioTelemetry launches offer to acquire LifeWatch BioTelemetry and LifeWatch announced in an April 9 press release that the 2 companies have entered a transaction agreement that states BioTelemetry will launch a tender offer to acquire all […]
Clinical Trials
Glaukos drops $6m on Dose Medical’s IOP sensor system
Glaukos (NYSE:GKOS) said today that it acquired Dose Medical‘s intraocular pressure sensor system assets for $5.5 million in cash, plus $9.5 million contingent upon development, clinical and regulatory milestones. The Dose Medical IOP sensor system includes a micro-invasive ocular implant that captures and stores a glaucoma patient’s short-interval IOP measurements. The system transmits data to […]
Adgero touts data for photodynamic drug-device combo
Adgero Biopharmaceuticals touted positive clinical data from studies of its late-stage photodynamic therapy platform for the treatment of cutaneous oncology indications, including unresectable metastatic breast cancer. The Princeton, N.J.-based company’s REM-001 therapy consists of a laser light source, a light delivery device and a photosensitizer drug. The therapy has been evaluated in 4 Phase II/III clinical […]
Cytori wins FDA nod for cell therapy pilot trial
Cytori Therapeutics (NSDQ:CYTX) said today that the FDA approved an Investigational Device Exemption for a pilot trial of the company’s cell therapy in patients with thermal burn injury. The Relief trial is a part of Cytori’s ongoing R&D efforts under its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and […]
Canadian government, JDRF ink $30m partnership to support diabetes research
Canada’s Minister of Health, Jane Philpott, said today that the Canadian Institutes of Health Research inked a $30 million partnership with the Juvenile Diabetes Research Foundation to support clinical research for Type I diabetes. Both groups have agreed to invest $15 million to the deal. “The government of Canada recognizes the impact that Type I diabetes […]
Medtech stories we missed this week: April 7, 2017
New studies for umbilical cord allografts and tumor targeting were published this week while another company received European CE Marking. Here are some medtech stories we missed this week but thought were still worth mentioning. 1. AMNIOX touts new umbilical cord study AMNIOX Medical announced that it has published the results of 3 studies that demonstrate […]
Bellerophon touts effects of inhaled nitric oxide in pulmonary arterial hypertension
Bellerophon Therapeutics (NSDQ:BLPH) presented data for its INOpulse nitric oxide device in patients with pulmonary arterial hypertension at the International Society of Heart and Lung Transplantation’s annual meeting. Researchers studied the effects of pulsed inhaled nitric oxide, delivered by the INOpulse device in 10 patients with pulmonary arterial hypertension both before and after exercise. The […]
Patients twice as likely to take anticoagulants with artificial intelligence platform
Researchers from the Stern Stroke Center at Montefiore Medical Center published trial results this week showing that stroke survivors were twice as likely to take anticoagulants when using an artificial intelligence platform compared to patients receiving standard therapies. The AI platform, AiCure, features software algorithms on smartphones that confirm patient identify, medication and drug ingestion. […]
Keystone Nano launches clinical trial for NanoLiposome cancer therapy
Keystone Nano said today that it has begun clinical testing for its ceramide NanoLiposome cancer therapy. The Phase I trial plans to evaluate the company’s NanoLiposome as a targeted treatment for solid tumors. Ceramide is a lipid that has demonstrated efficacy in liver cancer, breast cancer, leukemia and pancreatic cancer. Preclinical evidence has shown that […]
AcelRx touts data from Dsuvia pain relief trials
AcelRx Pharmaceuticals (NSDQ:ACRX) touted efficacy and safety data today for its pain reliever, Dsuvia. The company’s lead drug candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in any country. The 4 late-phase studies enrolled 480 patients total. In 2 randomized studies, enrolled patients underwent bunionectomy […]